Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company focused on immunotherapy that filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2021, covering its most recent quarterly period. The filing, carrying accession number 0001410578-21-000091, reflects the company's obligations as a publicly reporting entity in the life sciences and immunology sector. Quarterly reports of this type give investors a periodic window into a company's financial condition, operating results, and material developments as it progresses through its public-company lifecycle. For comprehensive filing history, sponsor details, deal timelines, and real-time analytics on ESLA and the broader SPAC universe, sign up for full data on SpacDesk.